when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

ZEALAND PHARMA · news · pharmadog

← back to ZEALAND PHARMA

News mentioning ZEALAND PHARMA

36 stories

3dBoehringer, Zealand’s obesity drug doesn’t elevate heart risk in key late-stage testbiospace

24dShould amylin have been obesity therapeutics’ primary target from the start?biospace

29dZealand pens up to $1.2B deal with Generate for AI-designed obesity, metabolic drugsbiospace

29dZealand inks up to $1.3B deal for AI-designed obesity treatmentsendpoints

29dZealand inks $1.2B Generate pact to add multispecific proteins to obesity pipelinefiercebiotech

Oct 13, 26Roche extends China deal streak with $1B pact for RNAi obesity drugbiopharma dive

Oct 13, 26Roche inks $1.2B deal with China's Rona to enter emerging ALK7 obesity racefiercebiotech

Oct 9, 26FDA review docs spark Revolution sell-off; Zealand diabetes data underwhelm analystsbiopharma dive

Oct 8, 26Zealand, Roche topline a Phase 2 study for amylin drug, though Lilly remains an obstacleendpoints

Oct 8, 26Despite Zealand asset’s ‘intriguing’ weight loss, analysts underwhelmed by blood sugar numbersbiospace

Oct 8, 26Zealand, Roche’s ‘intriguing’ weight loss for amylin drug soured by blood sugar datafiercebiotech

Oct 2, 26STAT+: Pharmalittle: We’re reading about the 340B drug pilot program, an obesity drug disappointment, and morestat

Oct 1, 263 takeaways from a European obesity scientific meetingbiopharma dive

Oct 1, 26Zealand dips as Boehringer Ingelheim-partnered weight loss drug fails to impress—againbiospace

Oct 1, 26Zealand's stock slides as Boehringer-partnered obesity drug underwhelms again in phase 3fiercebiotech

Sep 30, 26Lilly raises diabetes weight-loss bar with amylin-Zepbound combofiercebiotech

Sep 30, 26Roche, Zealand see phase 2 amylin weight loss peak at mid-dose, start pivotal programfiercebiotech

Sep 29, 26Roche cuts muscle-sparing obesity drug after mid-stage disappointmentbiospace

Sep 23, 26Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitzbiospace

Sep 22, 26Viking achieves 'maintenance trifecta' as GLP-1/GIP dual agonist exceeds expectationsbiospace

Sep 22, 26Roche’s Carmot asset normalizes blood sugar, cuts weight in Phase 2 diabetes trialbiospace

Aug 28, 26Why Roche is 'really excited' about a UCN2 analog for obesity after seeing preclinical datafiercebiotech

Aug 27, 26Myriad catalysts on deck for obesity’s brightest stars as market continues to acceleratebiospace

Aug 24, 26Roche commits to lean-mass preservation with Hanmi obesity dealbiopharma dive

Aug 24, 26Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanismfiercebiotech

Aug 20, 26Boehringer places phase 1 study of investigational drug on hold to examine ‘safety event’fiercebiotech

Aug 14, 26Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myersbiopharma dive

Aug 13, 26Zealand sells milestone, royalty rights to rare blood cancer asset for up to $100Mbiospace

Aug 13, 26Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decisionfiercebiotech

Jul 24, 26Roche cans one Carmot obesity asset as another shows best-in-class potentialbiospace

← prevpage 1 of 2next →